Core Insights - The article highlights the issuance of a new patent for GerlinC, a ready-to-use liquid formulation that enhances efficiency and focus for surgeons, leading to a 10-minute procedure [1] - Regentis Biomaterials Ltd. has a robust intellectual property portfolio with 35 issued patents globally [1] - GerlinC is currently undergoing a pivotal FDA trial and has received regulatory approval in the EU, marking it as the world's first off-the-shelf regenerative treatment for knee cartilage repair [1] Company Developments - The U.S. Patent and Trademark Office granted a patent for "Organic Solvent Free Compositions Compromising Protein-Polymer Conjugates and Uses Thereof," which pertains to the production processes of GerlinC that eliminate the use of organic solvents [1] - The focus on innovative tissue repair solutions positions Regentis as a key player in the regenerative medicine sector [1]